Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Iovance Biotherapeutics Inc's Business Segments
Iovance Biotherapeutics Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2026
Reportable Segments
1
Largest Segment
Single reportable segment
Total Revenue
$ 71
Countrys Reported
1
Revenue Share by Reportable Segment - Q1 FY2026
- Single reportable segment100%
Revenue by Reportable Segment - Q1 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Single reportable segment | $ 71 | 100% |
Revenue Share by Country - Q1 FY2026
- US98.7%
Revenue by Geographic Country - Q1 FY2026
| Country | Revenue (Millions) | % of Total |
|---|---|---|
| US | $ 70 | 98.7% |
Revenue by Product & Service Category - Q1 FY2026
- Amtagvi84.3%
- Proleukin15.7%
Revenue by Product & Service Category - Q1 FY2026
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Amtagvi | $ 60 | 84.3% |
| Proleukin | $ 11 | 15.7% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Iovance Biotherapeutics Inc
Iovance Biotherapeutics Inc. is a biotechnology company that specializes in developing novel cancer immunotherapies. The company is headquartered in San Carlos, California, and was founded in 200
The primary focus of Iovance Biotherapeutics is to harness the power of a patient's own immune system to target and eliminate cancer cells. The company's innovative approach involves isolating white blood cells called tumor-infiltrating lymphocytes (TILs) from a patient's tumor tissue and expanding them in the lab to create a personalized treatment.
Iovance's lead product candidate is LN-144, also known as lifileucel, which is being developed for the treatment of metastatic melanoma and other solid tumors. LN-144 is created by enriching TILs from the patient's tumor and expanding them in the lab to increase their number. These activated TILs are then infused back into the patient to recognize and kill cancer cells.
The company's second product candidate is called LN-145, also known as lifileucel, which is being developed for the treatment of cervical cancer. LN-145 follows a similar approach as LN-144, where TILs are extracted from the patient's tumor and expanded in the lab to create a personalized therapy.
Iovance Biotherapeutics has also developed a proprietary technology platform called Tumor-Infiltrating Lymphocyte Therapy0 (TIL Therapy0), which helps in the efficient expansion of TILs for large-scale commercial production.
In addition to its clinical pipeline, Iovance Biotherapeutics is actively involved in research and development efforts to explore the potential of TIL therapy in other cancer indications. The company seeks to address the significant unmet need in cancer treatment through its cutting-edge immunotherapies.
Iovance Biotherapeutics collaborates with renowned academic institutions, cancer centers, and pharmaceutical companies to further advance its research and development initiatives. The company has established strategic partnerships with organizations like The National Cancer Institute, Moffitt Cancer Center, The University of Texas MD Anderson Cancer Center, and Merck.
As a publicly traded company, Iovance Biotherapeutics is listed on Nasdaq under the ticker symbol IOVA. The company has a team of experienced scientists, researchers, and industry professionals who are dedicated to advancing the field of immuno-oncology and revolutionizing cancer treatment.
Overall, Iovance Biotherapeutics Inc. is at the forefront of developing personalized cancer immunotherapies using TILs and has the potential to significantly impact the future of cancer treatment.
The primary focus of Iovance Biotherapeutics is to harness the power of a patient's own immune system to target and eliminate cancer cells. The company's innovative approach involves isolating white blood cells called tumor-infiltrating lymphocytes (TILs) from a patient's tumor tissue and expanding them in the lab to create a personalized treatment.
Iovance's lead product candidate is LN-144, also known as lifileucel, which is being developed for the treatment of metastatic melanoma and other solid tumors. LN-144 is created by enriching TILs from the patient's tumor and expanding them in the lab to increase their number. These activated TILs are then infused back into the patient to recognize and kill cancer cells.
The company's second product candidate is called LN-145, also known as lifileucel, which is being developed for the treatment of cervical cancer. LN-145 follows a similar approach as LN-144, where TILs are extracted from the patient's tumor and expanded in the lab to create a personalized therapy.
Iovance Biotherapeutics has also developed a proprietary technology platform called Tumor-Infiltrating Lymphocyte Therapy0 (TIL Therapy0), which helps in the efficient expansion of TILs for large-scale commercial production.
In addition to its clinical pipeline, Iovance Biotherapeutics is actively involved in research and development efforts to explore the potential of TIL therapy in other cancer indications. The company seeks to address the significant unmet need in cancer treatment through its cutting-edge immunotherapies.
Iovance Biotherapeutics collaborates with renowned academic institutions, cancer centers, and pharmaceutical companies to further advance its research and development initiatives. The company has established strategic partnerships with organizations like The National Cancer Institute, Moffitt Cancer Center, The University of Texas MD Anderson Cancer Center, and Merck.
As a publicly traded company, Iovance Biotherapeutics is listed on Nasdaq under the ticker symbol IOVA. The company has a team of experienced scientists, researchers, and industry professionals who are dedicated to advancing the field of immuno-oncology and revolutionizing cancer treatment.
Overall, Iovance Biotherapeutics Inc. is at the forefront of developing personalized cancer immunotherapies using TILs and has the potential to significantly impact the future of cancer treatment.
Iovance Biotherapeutics Inc. is at the forefront of biotechnology, concentrating on producing advanced cell-based cancer immunotherapies. The companys primary focus is on harnessing the potential of the patient’s immune system to combat cancer effectively and enhance clinical outcomes. Below is an extensive description of the segments, products, and services offered by Iovance Biotherapeutics.
Segments
1. Tumor-Infiltrating Lymphocyte (TIL) Therapy:
This segment is the cornerstone of Iovance Biotherapeutics innovation, centered on harvesting and manipulating tumor-infiltrating lymphocytes (TILs) to create personalized immunotherapies. TIL therapy leverages the bodys natural immune response, aiming to expand and enhance the capabilities of these immune cells to recognize and eradicate cancer cells post-infusion. The methodology involves a multi-step process: extraction of TILs from a patient’s tumor, ex vivo expansion and activation of these cells in a laboratory setting, and finally reintroducing them into the patient’s bloodstream. This process aims not just for tumor reduction but for durable, long-lasting responses to cancer.
Products and Services
1. LN-144 (Lifileucel):
LN-144 is Iovances flagship product candidate specifically being developed for treating metastatic melanoma. The creation of Lifileucel begins with isolating TILs from a patient’s tumor sample. These TILs are then genetically modified and cultured to increase their numbers and enhance their tumor-targeting capabilities. This regained immune vigor is intended to help the patient’s body combat the advanced stages of melanoma more effectively. Results from clinical trials have shown significant promise, showcasing LN-144s potential to improve patient prognoses.
2. LN-145 (Cililimab):
Similar in methodology to LN-144, LN-145 is oriented towards the treatment of cervical cancer and head and neck cancers. The extraction and modification process parallels that of Lifileucel, focusing on tailoring the TILs to better recognize and attack specific cancer cells. Through ongoing clinical trials, LN-145 seeks to establish its efficacy and safety profile, potentially offering new hope for patients battling these challenging cancer types.
3. Collaborative Research and Licensing Agreements:
Iovance Biotherapeutics is committed to advancing cancer treatment not only through its direct product development but also by fostering partnerships with academic institutions and pharmaceutical companies. These collaborations may involve licensing pioneering technologies, pooling research insights, and conducting joint clinical trials. The goal is to accelerate the discovery and commercialization of novel immunotherapeutics, paving the way for broader applications in cancer treatment.
4. Clinical Development and Regulatory Affairs:
The company places a strong emphasis on the integrity and rigor of its clinical development processes. Iovance Biotherapeutics provides comprehensive services that encompass the design and execution of clinical trials, navigational support for regulatory approvals, and ongoing compliance with regulatory frameworks. This commitment ensures that their therapies undergo thorough testing and validation before reaching the patient population, thereby prioritizing safety and efficacy.
5. Manufacturing and Supply Chain:
Iovance operates state-of-the-art manufacturing facilities dedicated to the production of cell-based therapies, specifically TILs. The organization ensures that TILs are harvested, expanded, and modified in a controlled and sterile environment, which is critical to maintaining the quality and effectiveness of the therapies. The companys manufacturing processes are designed to scale efficiently, accommodating the bespoke nature of each patient’s treatment while adhering to stringent quality control measures. Moreover, Iovance manages a robust supply chain to ensure the timely availability of its products, supporting both clinical and potential commercial distribution.
Conclusion
Iovance Biotherapeutics Inc. is deeply invested in revolutionizing cancer treatment through the innovation of TIL therapies. With its sophisticated pipeline of products, commitment to collaborative research, steady focus on clinical and regulatory excellence, and advanced manufacturing capabilities, the company aims to significantly impact patient care and outcomes in oncology. Through these endeavors, Iovance is striving toward the possibility of transformative therapies that empower patients by leveraging their own immune responses to combat cancer.
Segments
1. Tumor-Infiltrating Lymphocyte (TIL) Therapy:
This segment is the cornerstone of Iovance Biotherapeutics innovation, centered on harvesting and manipulating tumor-infiltrating lymphocytes (TILs) to create personalized immunotherapies. TIL therapy leverages the bodys natural immune response, aiming to expand and enhance the capabilities of these immune cells to recognize and eradicate cancer cells post-infusion. The methodology involves a multi-step process: extraction of TILs from a patient’s tumor, ex vivo expansion and activation of these cells in a laboratory setting, and finally reintroducing them into the patient’s bloodstream. This process aims not just for tumor reduction but for durable, long-lasting responses to cancer.
Products and Services
1. LN-144 (Lifileucel):
LN-144 is Iovances flagship product candidate specifically being developed for treating metastatic melanoma. The creation of Lifileucel begins with isolating TILs from a patient’s tumor sample. These TILs are then genetically modified and cultured to increase their numbers and enhance their tumor-targeting capabilities. This regained immune vigor is intended to help the patient’s body combat the advanced stages of melanoma more effectively. Results from clinical trials have shown significant promise, showcasing LN-144s potential to improve patient prognoses.
2. LN-145 (Cililimab):
Similar in methodology to LN-144, LN-145 is oriented towards the treatment of cervical cancer and head and neck cancers. The extraction and modification process parallels that of Lifileucel, focusing on tailoring the TILs to better recognize and attack specific cancer cells. Through ongoing clinical trials, LN-145 seeks to establish its efficacy and safety profile, potentially offering new hope for patients battling these challenging cancer types.
3. Collaborative Research and Licensing Agreements:
Iovance Biotherapeutics is committed to advancing cancer treatment not only through its direct product development but also by fostering partnerships with academic institutions and pharmaceutical companies. These collaborations may involve licensing pioneering technologies, pooling research insights, and conducting joint clinical trials. The goal is to accelerate the discovery and commercialization of novel immunotherapeutics, paving the way for broader applications in cancer treatment.
4. Clinical Development and Regulatory Affairs:
The company places a strong emphasis on the integrity and rigor of its clinical development processes. Iovance Biotherapeutics provides comprehensive services that encompass the design and execution of clinical trials, navigational support for regulatory approvals, and ongoing compliance with regulatory frameworks. This commitment ensures that their therapies undergo thorough testing and validation before reaching the patient population, thereby prioritizing safety and efficacy.
5. Manufacturing and Supply Chain:
Iovance operates state-of-the-art manufacturing facilities dedicated to the production of cell-based therapies, specifically TILs. The organization ensures that TILs are harvested, expanded, and modified in a controlled and sterile environment, which is critical to maintaining the quality and effectiveness of the therapies. The companys manufacturing processes are designed to scale efficiently, accommodating the bespoke nature of each patient’s treatment while adhering to stringent quality control measures. Moreover, Iovance manages a robust supply chain to ensure the timely availability of its products, supporting both clinical and potential commercial distribution.
Conclusion
Iovance Biotherapeutics Inc. is deeply invested in revolutionizing cancer treatment through the innovation of TIL therapies. With its sophisticated pipeline of products, commitment to collaborative research, steady focus on clinical and regulatory excellence, and advanced manufacturing capabilities, the company aims to significantly impact patient care and outcomes in oncology. Through these endeavors, Iovance is striving toward the possibility of transformative therapies that empower patients by leveraging their own immune responses to combat cancer.